| 1 |
Fan GH, Zhang CZ, Gao FQ, Wei XY, Ling SB, Wang K, Wang JG, Zheng SS, Nikfarjam M, Xu X. A mixed blessing for liver transplantation patients - Rapamycin. Hepatobiliary Pancreat Dis Int 2023;22:14-21. [PMID: 36328894 DOI: 10.1016/j.hbpd.2022.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Liu P, Wang X, Liu H, Wang SX, Xu QG, Wang L, Xu X, Cai JZ. Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience. Hepatobiliary Pancreat Dis Int 2023;22:34-40. [PMID: 36513566 DOI: 10.1016/j.hbpd.2022.11.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Lerut J, Lai Q. Comments on: Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation 2023. [PMID: 36706072 DOI: 10.1097/TP.0000000000004488] [Reference Citation Analysis]
|
| 4 |
Mei Z, Gao X, Pan C, Wu Q, Wang S, Qian J, Xu Z, Xu K, Zhou L, Zhen S. Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1(+) CD8(+) T cells in HCC via blocking VEGFR2. Cancer Sci 2023. [PMID: 36609997 DOI: 10.1111/cas.15719] [Reference Citation Analysis]
|
| 5 |
Jiang J, Huang H, Chen R, Lin Y, Ling Q. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors? Front Immunol 2023;14:1092401. [PMID: 36875077 DOI: 10.3389/fimmu.2023.1092401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Lichtenstern C, Lund F, Müller M, Schmidt J, Mayer K, Weigand MA. Intensivtherapie im Rahmen der Transplantation solider Organe. Die Intensivmedizin 2023. [DOI: 10.1007/978-3-642-54675-4_101-2] [Reference Citation Analysis]
|
| 7 |
Umman V, Zeytunlu M, Emre S. Immunosuppression after Liver Transplantation in Pediatric Population. Pediatric Solid Organ Transplantation 2023. [DOI: 10.1007/978-981-19-6909-6_31] [Reference Citation Analysis]
|
| 8 |
Zhang G, Duan B, Li G. mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis. Clin Transplant 2022;36:e14823. [PMID: 36124430 DOI: 10.1111/ctr.14823] [Reference Citation Analysis]
|
| 9 |
Rasha F, Paul S, Simon TG, Hoshida Y. Hepatocellular Carcinoma Chemoprevention with Generic Agents. Semin Liver Dis 2022;42:501-13. [PMID: 36104114 DOI: 10.1055/a-1942-6693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Lee HS, Kim JY, Ro SW, Kim MS, Kim H, Joo DJ. Antitumor Effect of Low-Dose of Rapamycin in a Transgenic Mouse Model of Liver Cancer. Yonsei Med J 2022;63:1007-15. [PMID: 36303309 DOI: 10.3349/ymj.2022.0247] [Reference Citation Analysis]
|
| 11 |
Choi MC, Min EK, Lee JG, Joo DJ, Kim MS, Kim DG. Antiplatelet Drugs on the Recurrence of Hepatocellular Carcinoma after Liver Transplantation. Cancers (Basel) 2022;14. [PMID: 36358749 DOI: 10.3390/cancers14215329] [Reference Citation Analysis]
|
| 12 |
Dennis C, Prince DS, Moayed-alaei L, Remash D, Carr-boyd E, Bowen DG, Strasser SI, Crawford M, Pulitano C, Kench J, Mccaughan GW, Mckenzie C, Liu K. Association between vessels that encapsulate tumour clusters vascular pattern and hepatocellular carcinoma recurrence following liver transplantation. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.997093] [Reference Citation Analysis]
|
| 13 |
Kim SJ, Kim JM. Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review. Clin Mol Hepatol 2022;28:739-53. [PMID: 35468711 DOI: 10.3350/cmh.2022.0060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Reivell V, Hagman H, Haux J, Jorns C, Lindnér P, Taflin H. SOULMATE: the Swedish study of liver transplantation for isolated colorectal cancer liver metastases not suitable for operation or ablation, compared to best established treatment-a randomized controlled multicenter trial. Trials 2022;23:831. [PMID: 36180944 DOI: 10.1186/s13063-022-06778-9] [Reference Citation Analysis]
|
| 15 |
Duan J, Huang Z, Nice EC, Xie N, Chen M, Huang C. Current advancements and future perspectives of long noncoding RNAs in lipid metabolism and signaling. J Adv Res 2022:S2090-1232(22)00188-6. [PMID: 35973552 DOI: 10.1016/j.jare.2022.08.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 16 |
Bhangui P. Liver transplantation and portal vein tumour thrombus: futile enterprise? Curr Opin Organ Transplant 2022;27:312-9. [PMID: 36354257 DOI: 10.1097/MOT.0000000000000997] [Reference Citation Analysis]
|
| 17 |
Shang C, Ke M, Liu L, Wang C, Liu Y, Zheng X. Exosomes From Cancer-Associated Mesenchymal Stem Cells Transmit TMBIM6 to Promote the Malignant Behavior of Hepatocellular Carcinoma via Activating PI3K/AKT Pathway. Front Oncol 2022;12:868726. [PMID: 35720012 DOI: 10.3389/fonc.2022.868726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Ilmer M, Guba MO. Liver Transplant Oncology: Towards Dynamic Tumor-Biology-Oriented Patient Selection. Cancers 2022;14:2662. [DOI: 10.3390/cancers14112662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Kim DG, Kim SH, Hwang S, Hong SK, Ryu JH, Kim BW, You YK, Choi D, Kim DS, Nah YW, Cho JY, Kim TS, Hong G, Joo DJ, Kim MS, Kim JM, Lee JG, Kotry Study Group. Safety of Tacrolimus Monotherapy within 12 Months after Liver Transplantation in the Era of Reduced Tacrolimus and Mycophenolate Mofetil: National Registry Study. J Clin Med 2022;11:2806. [PMID: 35628939 DOI: 10.3390/jcm11102806] [Reference Citation Analysis]
|
| 20 |
Su RY, Ling SB, Shan QN, Wei XY, Wang R, Jia CK, Zhuang L, Shen T, Ding LM, Xu ZD, Luo LB, Sun LB, Li GM, Fang TS, Jiang N, Zhang K, Su ZJ, Peng ZH, Lang R, Jiang T, He Q, Ye LS, Yang Y, He YT, Guo WZ, Lan LG, Sun XY, Chen D, Chen ZS, Zhou DW, Ye SJ, Ye QF, Tian M, Shi JH, Wang B, Liu J, Lu Q, Rao W, Cai JZ, Lv T, Yang JY, Wang PS, Zhong L, Ma JS, Li QG, Wu SD, Lu CJ, Lu CD, Zhang DH, Wang X, Li ZQ, Teng MJ, Li JJ, Jiang WT, Li JH, Zhang QB, Zhu NQ, Wang ZX, He K, Xia Q, Song SH, Fu ZR, Qiu W, Lv GY, Song RP, Wang JZ, Wang Z, Zhou J, Chen G, Zhao YP, Li L, Hu ZM, Luo QJ, Si ZZ, Xie B, He XS, Guo ZY, Zheng SS, Xu X. Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study. Hepatobiliary Pancreat Dis Int 2022;21:106-12. [PMID: 34583911 DOI: 10.1016/j.hbpd.2021.09.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 21 |
Luo Y, Teng F, Fu H, Ding GS. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. World J Gastrointest Oncol 2022; 14(1): 163-180 [DOI: 10.4251/wjgo.v14.i1.163] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 22 |
Colmenero J, Tabrizian P, Bhangui P, Pinato DJ, Rodríguez-Perálvarez ML, Sapisochin G, Bhoori S, Pascual S, Senzolo M, Al-Adra D, Herrero JI, Petrowsky H, Dawson LA, Hosni A, Kutzke JL, Gastaca M, Watt KD. De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference. Transplantation 2022;106:e30-45. [PMID: 34905760 DOI: 10.1097/TP.0000000000003998] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 23 |
Lerut J, Lai Q. Deceased Donor Liver Transplantation: The Pendulum of Visions and Ideas. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases 2022. [DOI: 10.1007/978-981-19-0063-1_64] [Reference Citation Analysis]
|
| 24 |
Zhang H, Zhao J, Yang W, Li Z, Gong L, Li Y. Liver Cancer: Interdisciplinary Approach. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_96] [Reference Citation Analysis]
|
| 25 |
Houben P, Schimmack S, Unterrainer C, Döhler B, Mehrabi A, Süsal C. Rare Malignant Indications for Liver Transplantation: A Collaborative Transplant Study Report. Front Surg 2021;8:678392. [PMID: 34926560 DOI: 10.3389/fsurg.2021.678392] [Reference Citation Analysis]
|
| 26 |
Serenari M, Cappelli A, Cucchetti A, Mosconi C, Strigari L, Monari F, Ravaioli M, Rizzini EL, Fanti S, Golfieri R, Cescon M. Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transpl 2021;27:1758-66. [PMID: 34355489 DOI: 10.1002/lt.26257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 27 |
Bracic Tomazic S, Schatz C, Haybaeck J. Translational Regulation in Hepatocellular Carcinogenesis. Drug Des Devel Ther 2021;15:4359-69. [PMID: 34703211 DOI: 10.2147/DDDT.S255582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 28 |
Vogel A, Sterneck M, Vondran F, Waidmann O, Klein I, Lindig U, Nadalin S, Settmacher U, Tacke F, Schlitt HJ, Wege H. [The use of immuno-oncologic therapy in hepatocellular carcinoma in the context of liver transplantation. An interdisciplinary benefit/risk assessment]. Z Gastroenterol 2021. [PMID: 34670296 DOI: 10.1055/a-1649-8643] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 29 |
Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 30 |
Zhao Y, Liu Y, Zhou L, Du GS, He Q. Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(9): 953-966 [PMID: 34621472 DOI: 10.4240/wjgs.v13.i9.953] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Kim JM. Can hepatocellular carcinoma recurrence be prevented after liver transplantation? Clin Mol Hepatol 2021;27:562-3. [PMID: 34551504 DOI: 10.3350/cmh.2021.0276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 32 |
Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. World J Clin Oncol 2021; 12(8): 623-645 [PMID: 34513597 DOI: 10.5306/wjco.v12.i8.623] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 33 |
Qing X, Xu W, Zong J, Du X, Peng H, Zhang Y. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 2021;9:64. [PMID: 34419152 DOI: 10.1186/s40364-021-00319-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 34 |
Niu M, Yi M, Li N, Wu K, Wu K. Advances of Targeted Therapy for Hepatocellular Carcinoma. Front Oncol 2021;11:719896. [PMID: 34381735 DOI: 10.3389/fonc.2021.719896] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 35 |
Gül-Klein S, Hegermann H, Röhle R, Schmelzle M, Tacke F, Schöning W, Öllinger R, Dziodzio T, Maier P, Plewe JM, Horst D, Sauer IM, Pratschke J, Lachmann N, Eurich D. Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies. J Inflamm Res 2021;14:2697-712. [PMID: 34188517 DOI: 10.2147/JIR.S307778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 36 |
Lerut J, Foguenne M, Lai Q. Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score. Updates Surg 2021. [PMID: 34003479 DOI: 10.1007/s13304-021-01078-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 37 |
Ossami Saidy RR, Postel MP, Pflüger MJ, Schoening W, Öllinger R, Gül-Klein S, Schmelzle M, Tacke F, Pratschke J, Eurich D. Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1617. [PMID: 33807392 DOI: 10.3390/cancers13071617] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 38 |
Cavaliere D, Parini D, Marano L, Cipriani F, Di Marzo F, Macrì A, D'Ugo D, Roviello F, Gronchi A; SICO (Italian Society of Surgical Oncology). Surgical management of oncologic patient during and after the COVID-19 outbreak: practical recommendations from the Italian society of Surgical Oncology. Updates Surg 2021;73:321-9. [PMID: 33184782 DOI: 10.1007/s13304-020-00921-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
|
